RESUMEN
Resumen: Objetivo: Determinar la prevalencia del uso complementario de la herbolaria en pacientes de oncología. Materiales y Métodos: El presente estudio fue de tipo observacional, transversal, descriptivo y prolectivo. Se llevó a cabo un muestreo no probabilístico. En el estudio se incluyeron a 100 pacientes que acudieron al área de oncología del Hospital de Alta Especialidad de Ciudad Victoria "Bicentenario 2010" (HRAEV) durante el periodo del estudio y que cumplieron con los criterios de selección señalados para esta investigación. Resultados: Se realizaron 100 encuestas a pacientes oncológicos, de los cuales el 55% fue de sexo femenino. Dicha población presenta una edad promedio de 48.2 años. Respecto al origen de los pacientes, el 67% radica en Cd. Victoria. El rango de nivel educativo entre los entrevistados osciló entre preparatoria y secundaria. Los cuales pertenecen a clase media. Existe una prevalencia del 82% en el uso de tratamientos alternativos para tratar la patología, de los cuales el 76% emplea el uso de la herbolaria como coadyuvante en las diferentes enfermedades que se tratan en el hospital. Las principales plantas empleadas son: la Mariguana (Cannabis sativa) en un 45%, el 23% Noni (Morinda citrifolia) y el 12% Bardana (Arctium lappa). Conclusión: El uso de la medicina alternativa complementaria es frecuente en pacientes oncológicos, destacando la herbolaria. Por lo anterior, el comprender la dinámica de la implementación de terapias alternativas como lo es la herbolaria, permitirá comprender y guiar al paciente en su proceso de ciclos oncológicos y minimizar los efectos secundarios.
Abstract: Objective: To determine the prevalence of the complementary use of herbal medicine in oncology patients. Materials and methods: This study was observational, cross-sectional, descriptive and prolective. A non-probabilistic sampling was carried out. The study included 100 patients who attended the oncology area of the Hospital de Alta Especialidad de Ciudad Victoria "Bicentenario 2010" (HRAEV) during the study period and who met the selection criteria indicated for this research. Results: 100 surveys were carried out on cancer patients, of which 55% were female. This population has an average age of 48.2 years. Regarding the origin of the patients, 67% reside in Cd. Victoria. The range of educational level among the interviewees oscillated between high school and middle school. who belong to the middle class. There is a prevalence of 82% in the use of alternative treatments to treat the pathology, of which 76% employ the use of herbal medicine as an adjuvant in the different diseases that are treated in the hospital. The main plants used are: 45% Marijuana (Cannabis sativa), 23% Noni (Morinda citrifolia) and 12% Burdock (Arctium lappa). Conclusion: The use of complementary alternative medicine is common in cancer patients, highlighting herbal medicine. Due to the above, understanding the dynamics of the implementation of alternative therapies such as herbalism, will allow understanding and guiding the patient in their oncological cycle process and minimizing side effects. KEY WORDS: naturopathy; oncology; alternative medicine.
RESUMEN
The use of new adjuvants in vaccine formulations is a subject of current research. Only few parenteral adjuvants have been licensed. We have developed a mucosal and parenteral adjuvant known as AFCo1 (Adjuvant Finlay Cochleate 1, derived from proteoliposomes of N. meningitidis B) using a dialysis procedure to produce them on lab scale. The immunogenicity of the AFCo1 produced by dialysis has been already evaluated, but it was necessary to demonstrate the feasibility of a larger-scale manufacturing process. Therefore, we used a crossflow diafiltration system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The aim of this work was to produce AFCo1 on pilot scale, while conserving the adjuvant properties. The proteoliposomes (raw material) were resuspended in a buffer containing sodium deoxycholate and were transformed into AFCo1 under the action of a calcium forming buffer. The detergent was removed from the protein solution by diafiltration to a constant volume. In this CFS, we used a hollow fiber cartridge from Amicon (polysulfona cartridge of 10 kDa porosity, 1mm channel diameter of fiber and 0.45 m² area of filtration), allowing production of a batch of up to 20 L. AFCo1 were successfully produced by tangential filtration to pilot scale. The batch passed preliminary stability tests. Nasal immunization of BALB/c mice, induced specific saliva IgA and serum IgG. The induction of Th1 responses were demonstrated by the induction of IgG2a, IFNγ and not IL-5. The adjuvant action over Neisseria (self) antigens and with co-administered (heterologous) antigens such as ovalbumin and a synthetic peptide from haemolytic Streptococcus B was also demonstrated.